Press release ·
IND for KL-101 now in effect
Keyline can now start the first clinical study of a protein it designed.
CAMBRIDGE, Mass., Mar. 18, 2026 · The Investigational New Drug (IND) application for KL-101 is now in effect. The US Food and Drug Administration did not place a clinical hold within the 30-day review period. Keyline plans to dose the first patient in a Phase 1 study later this year.
Forward-looking statements. This press release has forward-looking statements, such as plans for clinical studies, timing and the use of funds. They are based on what Keyline knows today and are subject to risks and uncertainties, so actual results can be different. Keyline does not have to update them. (Sample text for a demo site.)